Advertisement

Breast Cancer Research and Treatment

, Volume 158, Issue 1, pp 67–77 | Cite as

Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer

  • Banu K. Arun
  • Yun Gong
  • Diane Liu
  • Jennifer K. Litton
  • Angelica M. Gutierrez-Barrera
  • J. Jack Lee
  • Lana Vornik
  • Nuhad K. Ibrahim
  • Terri Cornelison
  • Gabriel N. Hortobagyi
  • Brandy M. Heckman-Stoddard
  • Kimberly B. Koenig
  • Ricardo R. Alvarez
  • James L. Murray
  • Vicente Valero
  • Scott M. Lippman
  • Powel Brown
  • Nour Sneige
Clinical trial

Abstract

Selective estrogen receptor modulators (SERMs), tamoxifen, and raloxifene that reduce the risk of breast cancer are limited to only estrogen receptor-positive (ER+) breast cancer. In addition, patient acceptance of SERMs is low due to toxicity and intolerability. New agents with improved toxicity profile that reduce risk of ER-negative breast cancer are urgently needed. Observational studies show that statins can reduce breast cancer incidence and recurrence. The objective of this prospective short-term prevention study was to evaluate the effect of a lipophilic statin, atorvastatin, on biomarkers in breast tissue and serum of women at increased risk. Eligible participants included women with previous history of carcinoma in situ, or atypical hyperplasia, or 5 year breast cancer projected Gail risk >1.67 %, or lifetime breast cancer risk >20 % calculated by models including Claus, Tyrer-Cuzick, Boadicea, or BRCAPRO. Patients underwent baseline fine needle aspiration (FNA) of the breast, blood collection for biomarker analysis, and were randomized to either no treatment or atorvastatin at 10, 20, or 40 mg/day dose for 3 months. At 3 months, blood collection and breast FNA were repeated. Biomarkers included C-reactive protein (CRP), lipid profile, atorvastatin, and its metabolites, Ki-67, bcl-2, EGFR, and pEGFR. Baseline genotype for 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoAR) was also measured. Among 60 patients evaluated, a significant reduction in serum CRP, cholesterol and low-density lipoprotein (LDL), and increase in atorvastatin metabolites in serum and breast FNAs was demonstrated. No changes were observed in other tissue biomarkers. This study shows that atorvastatin and its metabolites are detectable in breast samples and may lower serum CRP among women without hyperlipidemia.

Keywords

Breast cancer risk Statins Atorvastatin Breast cancer biomarkers 

Notes

Acknowledgments

The study was funded by NCI-DCP# MDA05-6-01 contract grant. We thank Dr. Madhumita Ghosh for the critical reading and editing of the manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.

Supplementary material

10549_2016_3849_MOESM1_ESM.pdf (356 kb)
Supplementary material 1 (PDF 356 kb)

References

  1. 1.
    Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371–1388CrossRefPubMedGoogle Scholar
  2. 2.
    Goss PE, Ingle JN, Ales-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H, Investigators NCMS (2011) Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 364:2381–2391CrossRefPubMedGoogle Scholar
  3. 3.
    Savage L (2007) Researchers wonder why high-risk women are not taking chemoprevention drugs. J Natl Cancer Inst 99:913–914CrossRefPubMedGoogle Scholar
  4. 4.
    Arun B, Dunn BK, Ford LG, Ryan A (2010) Breast cancer prevention trials: large and small trials. Semin Oncol 37:367–383CrossRefPubMedGoogle Scholar
  5. 5.
    Bonovas S, Filioussi K, Tsavaris N, Sitaras NM (2005) Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol: Off J Am Soc Clin Oncol 23:8606–8612CrossRefGoogle Scholar
  6. 6.
    Chae YK, Valsecchi ME, Kim J, Bianchi AL, Khemasuwan D, Desai A, Tester W (2011) Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins. Cancer Investig 29:585–593CrossRefGoogle Scholar
  7. 7.
    Brewer TM, Masuda H, Liu DD, Shen Y, Liu P, Iwamoto T, Kai K, Barnett CM, Woodward WA, Reuben JM, Yang P, Hortobagyi GN, Ueno NT (2013) Statin use in primary inflammatory breast cancer: a cohort study. Br J Cancer 109:318–324CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Higgins MJ, Prowell TM, Blackford AL, Byrne C, Khouri NF, Slater SA, Jeter SC, Armstrong DK, Davidson NE, Emens LA, Fetting JH, Powers PP, Wolff AC, Green H, Thibert JN, Rae JM, Folkerd E, Dowsett M, Blumenthal RS, Garber JE, Stearns V (2012) A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer. Breast Cancer Res Treat 131:915–924CrossRefPubMedGoogle Scholar
  9. 9.
    Vinayak S, Schwartz EJ, Jensen K, Lipson J, Alli E, McPherson L, Fernandez AM, Sharma VB, Staton A, Mills MA, Schackmann EA, Telli ML, Kardashian A, Ford JM, Kurian AW (2013) A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk. Breast Cancer Res Treat 142:389–398CrossRefPubMedGoogle Scholar
  10. 10.
    YongLi J, Rounds T, Crocker AM, Sussman B, Hovey RC, Kingsley F, Muss H, Garber JE., Wood ME (2016) The effect of atorvastatin on breast cancer biomarkers in high-risk women. Cancer Prev Res 9:379–384CrossRefGoogle Scholar
  11. 11.
    Arun B, Valero V, Logan C, Broglio K, Rivera E, Brewster A, Yin G, Green M, Kuerer H, Gong Y, Browne D, Hortobagyi GN, Sneige N (2007) Comparison of ductal lavage and random periareolar fine needle aspiration as tissue acquisition methods in early breast cancer prevention trials. Clin Cancer Res 13:4943–4948CrossRefPubMedGoogle Scholar
  12. 12.
    Hermann M, Christensen H, Reubsaet JL (2005) Determination of atorvastatin and metabolites in human plasma with solid-phase extraction followed by LC-tandem MS. Anal Bioanal Chem 382:1242–1249CrossRefPubMedGoogle Scholar
  13. 13.
    Harper-Wynne C, Ross G, Sacks N, Salter J, Nasiri N, Iqbal J, A’Hern R, Dowsett M (2002) Effects of the Aromatase Inhibitor Letrozole on Normal Breast Epithelial Cell Proliferation and Metabolic Indices in Postmenopausal Women: a Pilot Study for Breast Cancer Prevention. Cancer Epidemiol Biomark Prev 11:614–621Google Scholar
  14. 14.
    Fabian CJ, Kimler BF, Zalles CM, Khan QJ, Mayo MS, Phillips TA, Simonsen M, Metheny T, Petroff BK (2007) Reduction in proliferation with six months of letrozole in women on hormone replacement therapy. Breast Cancer Res Treat 106:75–84CrossRefPubMedGoogle Scholar
  15. 15.
    Fabian C, Kimler B, Donnelly J, Sullivan D, Klemp J, Petroff B, Phillips T, Metheny T, Aversman S, Yeh H-W, Zalles C, Mills G, Hursting S (2013) Favorable modulation of benign breast tissue and serum risk biomarkers is associated with >10 % weight loss in postmenopausal women. Breast Cancer Res Treat 142:119–132CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Fabian CJ, Kimler BF, Zalles CM, Klemp JR, Petroff BK, Khan QJ, Sharma P, Setchell KDR, Zhao X, Phillips TA, Metheny T, Hughes JR, Yeh H-W, Johnson KA (2010) Reduction in Ki-67 in Benign Breast Tissue of High-Risk Women with the Lignan Secoisolariciresinol Diglycoside. Cancer Prev Res 3:1342–1350CrossRefGoogle Scholar
  17. 17.
    Fabian CJ, Kimler BF, Anderson J, Tawfik OW, Mayo MS, Burak WE Jr, O’Shaughnessy JA, Albain KS, Hyams DM, Budd GT, Ganz PA, Sauter ER, Beenken SW, Grizzle WE, Fruehauf JP, Arneson DW, Bacus JW, Lagios MD, Johnson KA, Browne D (2004) Breast cancer chemoprevention phase I evaluation of biomarker modulation by Arzoxifene, a third generation selective estrogen receptor modulator. Clin Cancer Res 10:5403–5417. doi: 10.1158/1078-0432.CCR-04-0171.CrossRefPubMedGoogle Scholar
  18. 18.
    Ollberding NJ, Kim Y, Shvetsov YB, Wilkens LR, Franke AA, Cooney RV, Maskarinec G, Hernandez BY, Henderson BE, Le Marchand L, Kolonel LN, Goodman MT (2013) Prediagnostic leptin, adiponectin, C-reactive protein, and the risk of postmenopausal breast cancer. Cancer Prev Res (Phila). 6:188–195CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Ghosh-Choudhury N, Mandal CC, Ghosh Choudhury G (2010) Simvastatin induces derepression of PTEN expression via NFkappaB to inhibit breast cancer cell growth. Cell Signal 22:749–758CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Rao S, Gray-Bablin J, Herliczek TW, Keyomarsi K (1999) The biphasic induction of p21 and p27 in breast cancer cells by modulators of cAMP is posttranscriptionally regulated and independent of the PKA pathway. Exp Cell Res 252:211–223CrossRefPubMedGoogle Scholar
  21. 21.
    Muck AO, Seeger H, Wallwiener D (2004) Inhibitory effect of statins on the proliferation of human breast cancer cells. Int J Clin Pharmacol Ther 42:695–700CrossRefPubMedGoogle Scholar
  22. 22.
    Gopalan A, Yu W, Sanders BG, Kline K (2013) Simvastatin inhibition of mevalonate pathway induces apoptosis in human breast cancer cells via activation of JNK/CHOP/DR5 signaling pathway. Cancer Lett 329:9–16CrossRefPubMedGoogle Scholar
  23. 23.
    Goard CA, Chan-Seng-Yue M, Mullen PJ, Quiroga AD, Wasylishen AR, Clendening JW, Sendorek DH, Haider S, Lehner R, Boutros PC, Penn LZ (2014) Identifying molecular features that distinguish fluvastatin-sensitive breast tumor cells. Breast Cancer Res Treat 143:301–312CrossRefPubMedGoogle Scholar
  24. 24.
    Park YH, Jung HH, Ahn JS, Im YH (2013) Statin induces inhibition of triple negative breast cancer (TNBC) cells via PI3 K pathway. Biochem Biophys Res Commun 439:275–279CrossRefPubMedGoogle Scholar
  25. 25.
    Boyd NF, McGuire V (1990) Evidence of association between plasma high-density lipoprotein cholesterol and risk factors for breast cancer. J Natl Cancer Inst 82:460–468CrossRefPubMedGoogle Scholar
  26. 26.
    Kitahara CM, Berrington de Gonzalez A, Freedman ND, Huxley R, Mok Y, Jee SH, Samet JM (2011) Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol: Off J Am Soc Clin Oncol 29:1592–1598CrossRefGoogle Scholar
  27. 27.
    Warner M, Gustafsson JA (2014) On estrogen, cholesterol metabolism, and breast cancer. N Engl J Med 370:572–573CrossRefPubMedGoogle Scholar
  28. 28.
    Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, Carver NJ, Pillai RV, Sullivan PM, Sondhi V, Umetani M, Geradts J, McDonnell DP (2013) 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science 342:1094–1098CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Novak A, Binnington B, Ngan B, Chadwick K, Fleshner N, Lingwood CA (2013) Cholesterol masks membrane glycosphingolipid tumor-associated antigens to reduce their immunodetection in human cancer biopsies. Glycobiology 23:1230–1239CrossRefPubMedGoogle Scholar
  30. 30.
    Mannello F, Tonti GA (2009) Statins and breast cancer: may matrix metalloproteinase be the missing link. Cancer Invest 27:466–470CrossRefPubMedGoogle Scholar
  31. 31.
    Yamamoto K, Miyazaki K, Higashi S (2010) Cholesterol sulfate alters substrate preference of matrix metalloproteinase-7 and promotes degradations of pericellular laminin-332 and fibronectin. J Biol Chem 285:28862–28873CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Borgquist S, Djerbi S, Ponten F, Anagnostaki L, Goldman M, Gaber A, Manjer J, Landberg G, Jirstrom K (2008) HMG-CoA reductase expression in breast cancer is associated with a less aggressive phenotype and influenced by anthropometric factors. Int J Cancer 123:1146–1153CrossRefPubMedGoogle Scholar
  33. 33.
    Bjarnadottir O, Romero Q, Bendahl PO, Jirstrom K, Ryden L, Loman N, Uhlen M, Johannesson H, Rose C, Grabau D, Borgquist S (2013) Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Breast Cancer Res Treat 138:499–508CrossRefPubMedGoogle Scholar
  34. 34.
    Lippman ME, Krueger KA, Eckert S, Sashegyi A, Walls EL, Jamal S, Cauley JA, Cummings SR (2001) Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants. J Clin Oncol 19:3111–3116PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Banu K. Arun
    • 1
  • Yun Gong
    • 1
  • Diane Liu
    • 2
  • Jennifer K. Litton
    • 1
  • Angelica M. Gutierrez-Barrera
    • 1
  • J. Jack Lee
    • 2
  • Lana Vornik
    • 3
  • Nuhad K. Ibrahim
    • 1
  • Terri Cornelison
    • 4
  • Gabriel N. Hortobagyi
    • 1
  • Brandy M. Heckman-Stoddard
    • 4
  • Kimberly B. Koenig
    • 1
  • Ricardo R. Alvarez
    • 1
  • James L. Murray
    • 1
  • Vicente Valero
    • 1
  • Scott M. Lippman
    • 3
  • Powel Brown
    • 3
  • Nour Sneige
    • 5
  1. 1.Breast Medical Oncology and Clinical Cancer GeneticsThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Department of BiostatisticsThe University of Texas MD Anderson Cancer CenterHoustonUSA
  3. 3.Clinical Cancer PreventionThe University of Texas MD Anderson Cancer CenterHoustonUSA
  4. 4.Division of Cancer PreventionNational Cancer InstituteRockvilleUSA
  5. 5.Department of PathologyThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations